Chemically modified antisense compounds increase exon 19 inclusion in LRP8 mRNA to restore signaling pathways disrupted in Alzheimer's Disease.
Antisense oligonucleotides normalize aberrant gene expression in precursor cells, correcting secondary defects that limit transplantation success.